Latest Insider Transactions at Madrigal Pharmaceuticals, Inc. (MDGL)
This section provides a real-time view of insider transactions for Madrigal Pharmaceuticals, Inc. (MDGL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of MADRIGAL PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of MADRIGAL PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 21
2025
|
Carole Huntsman Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,958
-1.59%
|
$1,086,690
$555.09 P/Share
|
|
Nov 13
2025
|
Richard S Levy Director |
SELL
Open market or private sale
|
Direct |
8,500
-2.36%
|
$4,437,000
$522.33 P/Share
|
|
Nov 13
2025
|
Richard S Levy Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,500
+13.18%
|
$93,500
$11.91 P/Share
|
|
Nov 05
2025
|
Kenneth Bate Director |
SELL
Open market or private sale
|
Direct |
16,575
-15.93%
|
$8,038,875
$485.61 P/Share
|
|
Nov 05
2025
|
Kenneth Bate Director |
BUY
Exercise of conversion of derivative security
|
Direct |
16,575
+27.12%
|
$3,265,275
$197.76 P/Share
|
|
Sep 09
2025
|
William John Sibold President and CEO |
SELL
Open market or private sale
|
Direct |
7,279
-6.63%
|
$3,239,155
$445.63 P/Share
|
|
Aug 21
2025
|
William John Sibold President and CEO |
SELL
Open market or private sale
|
Direct |
7,616
-3.27%
|
$3,046,400
$400.51 P/Share
|
|
Aug 20
2025
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
59,901
+0.24%
|
$23,001,984
$384.95 P/Share
|
|
Aug 18
2025
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
105,782
+0.31%
|
$38,504,648
$364.61 P/Share
|
|
Aug 18
2025
|
Shannon T Kelley General Counsel |
SELL
Open market or private sale
|
Direct |
1,304
-1.64%
|
$483,784
$371.08 P/Share
|
|
Aug 15
2025
|
Kenneth Bate Director |
SELL
Open market or private sale
|
Direct |
10,000
-22.74%
|
$3,650,000
$365.89 P/Share
|
|
Aug 15
2025
|
Kenneth Bate Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+44.2%
|
$160,000
$16.46 P/Share
|
|
Aug 13
2025
|
Paul A Friedman Director |
SELL
Open market or private sale
|
Direct |
129,172
-2.97%
|
$47,276,952
$366.29 P/Share
|
|
Aug 13
2025
|
Paul A Friedman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
129,172
+28.99%
|
$1,162,548
$9.45 P/Share
|
|
Aug 12
2025
|
Paul A Friedman Director |
SELL
Open market or private sale
|
Direct |
43,605
-2.07%
|
$15,479,775
$355.37 P/Share
|
|
Aug 12
2025
|
Paul A Friedman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
43,605
+15.89%
|
$392,445
$9.45 P/Share
|
|
Aug 12
2025
|
Rebecca Taub Director |
SELL
Open market or private sale
|
Direct |
43,263
-0.89%
|
$15,358,365
$355.31 P/Share
|
|
Aug 12
2025
|
Rebecca Taub Director |
BUY
Exercise of conversion of derivative security
|
Direct |
43,263
+7.9%
|
$389,367
$9.45 P/Share
|
|
Aug 11
2025
|
Paul A Friedman Director |
SELL
Open market or private sale
|
Direct |
3,203
-0.84%
|
$1,121,050
$350.62 P/Share
|
|
Aug 11
2025
|
Paul A Friedman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,203
+1.65%
|
$28,827
$9.45 P/Share
|
|
Aug 11
2025
|
Rebecca Taub Director |
SELL
Open market or private sale
|
Direct |
3,200
-0.34%
|
$1,120,000
$350.6 P/Share
|
|
Aug 11
2025
|
Rebecca Taub Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,200
+0.68%
|
$28,800
$9.45 P/Share
|
|
Aug 01
2025
|
Daniel J. Brennan Director |
BUY
Grant, award, or other acquisition
|
Direct |
967
+50.0%
|
-
|
|
Jul 18
2025
|
Paul A Friedman Director |
SELL
Open market or private sale
|
Direct |
1,400
-0.74%
|
$490,000
$350.03 P/Share
|
|
Jul 18
2025
|
Paul A Friedman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,400
+0.74%
|
$12,600
$9.45 P/Share
|
|
Jul 18
2025
|
Rebecca Taub Director |
SELL
Open market or private sale
|
Direct |
1,000
-0.22%
|
$350,000
$350.0 P/Share
|
|
Jul 18
2025
|
Rebecca Taub Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+0.22%
|
$9,000
$9.45 P/Share
|
|
Jul 17
2025
|
Rebecca Taub Director |
SELL
Open market or private sale
|
Direct |
2,657
-0.29%
|
$929,950
$350.79 P/Share
|
|
Jul 17
2025
|
Rebecca Taub Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,657
+0.57%
|
$23,913
$9.45 P/Share
|
|
Jul 17
2025
|
Paul A Friedman Director |
SELL
Open market or private sale
|
Direct |
2,700
-0.71%
|
$945,000
$350.84 P/Share
|
|
Jul 17
2025
|
Paul A Friedman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,700
+1.4%
|
$24,300
$9.45 P/Share
|
|
Jul 16
2025
|
Rebecca Taub Director |
SELL
Open market or private sale
|
Direct |
26,444
-0.79%
|
$9,334,732
$353.54 P/Share
|
|
Jul 16
2025
|
Rebecca Taub Director |
BUY
Exercise of conversion of derivative security
|
Direct |
26,444
+5.15%
|
$237,996
$9.45 P/Share
|
|
Jul 16
2025
|
Paul A Friedman Director |
SELL
Open market or private sale
|
Direct |
26,176
-1.85%
|
$9,240,128
$353.56 P/Share
|
|
Jul 16
2025
|
Paul A Friedman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
26,176
+10.93%
|
$235,584
$9.45 P/Share
|
|
Jun 20
2025
|
Kenneth Bate Director |
BUY
Grant, award, or other acquisition
|
Direct |
715
+21.39%
|
-
|
|
Jun 20
2025
|
Richard S Levy Director |
BUY
Grant, award, or other acquisition
|
Direct |
715
+3.26%
|
-
|
|
Jun 20
2025
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
2,860
+0.42%
|
-
|
|
Jun 20
2025
|
Jacqualyn A Fouse Director |
BUY
Grant, award, or other acquisition
|
Direct |
203
+15.62%
|
-
|
|
Jun 20
2025
|
Paul A Friedman Director |
BUY
Grant, award, or other acquisition
|
Direct |
715
+0.38%
|
-
|
|
Jun 20
2025
|
James M Daly Director |
BUY
Grant, award, or other acquisition
|
Direct |
715
+21.39%
|
-
|
|
May 15
2025
|
David Soergel Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,545
+50.0%
|
-
|
|
Apr 10
2025
|
Richard S Levy Director |
BUY
Exercise of conversion of derivative security
|
Direct |
9,470
+31.62%
|
$615,550
$65.06 P/Share
|
|
Mar 13
2025
|
Fred B Craves Director |
SELL
Open market or private sale
|
Direct |
7,742
-0.27%
|
$2,523,892
$326.58 P/Share
|
|
Mar 13
2025
|
Fred B Craves Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,742
+2.12%
|
$503,230
$65.06 P/Share
|
|
Mar 12
2025
|
Fred B Craves Director |
SELL
Open market or private sale
|
Direct |
7,728
-0.44%
|
$2,565,696
$332.58 P/Share
|
|
Mar 12
2025
|
Fred B Craves Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,728
+1.07%
|
$680,064
$88.06 P/Share
|
|
Mar 10
2025
|
Mardi Dier SVP and CFO |
SELL
Open market or private sale
|
Direct |
258
-2.41%
|
$83,334
$323.04 P/Share
|
|
Mar 10
2025
|
Jacqualyn A Fouse Director |
BUY
Grant, award, or other acquisition
|
Direct |
894
+50.0%
|
-
|
|
Mar 05
2025
|
William John Sibold President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
13,066
+10.02%
|
-
|